factor X

(redirected from Factor Xa)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.
Related to Factor Xa: factor IIa

factor X

[′fak·tər ′ten]
(biochemistry)
References in periodicals archive ?
The aPCC, rFVIIa, and PCC are hemostatic agents and contains a high concentration of coagulation factors and due to this property, they may overcome factor Xa inhibition by promoting TG.
To be clear, the anti-Xa assay is not a newcomer to the clinical laboratory, with its use widely implemented to measure the parenteral, antithrombin-dependent anticoagulants UFH, low molecular weight heparin (LMWH), and fondaparinux, all of which possess inhibitory activity towards factor Xa. The anti-Xa assay has shown utility as an alternative to aPTT for measuring UFH, with strong evidence demonstrating the capability of anti-Xa-based dosing nomograms to establish therapeutic anticoagulation faster and maintain therapeutic levels better than aPTT-based nomograms.
One of them is dabigatran etexilate, a thrombin inhibitor and ravaroxiban (Xeralto), a factor Xa inhibitor.
This study evaluated the comparative efficacy of 4FPCC in emergent reversal of factor Xa inhibitors and VKA in the setting of ICH.
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
(ii) For all the factor Xa inhibitors, use of anti-factor Xa activity level can reliably assess the degree of anticoagulation, both qualitatively and quantitatively, provided that the instruments are calibrated for the specific agents.
Alfa, "First reversal agent for factor Xa inhibitors, finally gains FDA approval," May 2018, http://TCTMD.com, http://www.tctmd.com/news/andexanet-alfa-first-reversal-age nt-factor-xa-inhibitors-finally-gains-fda-approval..
Anti factor Xa assay for effective monitoring of heparin: A case report.
Louis, MO); (2) direct thrombin inhibitor dabigatran (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT); (3) factor Xa antagonist rivaroxaban (Xarelto, Janssen Pharmaceuticals, Inc, Beerse, Belgium); (4) indirect thrombin and factor Xa inhibitor heparin (Fresenius Kabi USA, Schaumburg, IL).
Misselwitz, "The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor," Nature Reviews Drug Discovery, vol.
"As an industry, we need to address the significant unmet medical need for managing Factor Xa inhibitor-related major bleeding by bringing to market an antidote that specifically reverses anti-Factor Xa activity, the anticoagulant mechanism of these agents.